Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab)

INTRODUCTION: PF-06438179, a potential biosimilar to Remicade(®) (infliximab, Janssen Biotech, Inc.), is a chimeric mouse–human monoclonal antibody targeting human tumor necrosis factor alpha (TNF). METHODS: Analytical (small subset reported here) and nonclinical studies compared the structural, fun...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Adv Ther
Prif Awduron: Derzi, Mazin, Johnson, Theodore R., Shoieb, Ahmed M., Conlon, Hugh D., Sharpe, Penny, Saati, Andrew, Koob, Sarah, Bolt, Michael W., Lorello, Leslie G., McNally, Jim, Kirchhoff, Carol F., Smolarek, Teresa A., Leach, Michael W.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer Healthcare 2016
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5083783/
https://ncbi.nlm.nih.gov/pubmed/27585978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-016-0403-9
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg